TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06020989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib+Pemetrexed+Carboplatin
Description: Arm A will receive Lazertinib and Pemetrexed, Carboplatin combination. Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity. Pemetrexed(500 mg/m2) will be administered IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity. Carboplatin(AUC5) will be administered IV infusions on Day 1 of each 21-day cycle until 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lazertinib
Description: Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lazertinib
Description: Lazertinib will be given 240 mg once a day daily PO until disease progression or unacceptable toxicity.
Study: NCT05824195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread products
Description: Four intervention products were included in the study. Three experimental breads (quinoa 1, quinoa 2, quinoa 3) were developed, and consisted of white wheat breads substituted with the differrent quinoa types. The reference product included was a white wheat bread without quinoa. All intervention products contain 50 g available starch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread products
Description: Four intervention products were included in the study. Three experimental breads (quinoa 1, quinoa 2, quinoa 3) were developed, and consisted of white wheat breads substituted with the differrent quinoa types. The reference product included was a white wheat bread without quinoa. All intervention products contain 50 g available starch.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread products
Description: Four intervention products were included in the study. Three experimental breads (quinoa 1, quinoa 2, quinoa 3) were developed, and consisted of white wheat breads substituted with the differrent quinoa types. The reference product included was a white wheat bread without quinoa. All intervention products contain 50 g available starch.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Bread products
Description: Four intervention products were included in the study. Three experimental breads (quinoa 1, quinoa 2, quinoa 3) were developed, and consisted of white wheat breads substituted with the differrent quinoa types. The reference product included was a white wheat bread without quinoa. All intervention products contain 50 g available starch.
Study: NCT05949437

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yuga
Description: Traditional yoga body posture for 15 minutes, yoga breathing exercises for 30 minutes and meditation for 5 minutes for 12 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic exercises
Description: in form of treadmill according to the target exercise heart rate for 12 weeks
Study: NCT05381857

Intervention type: OTHER
Intervention: Human Biological Samples
Description: Blood, urine, nasal swab, fecal samples
Study: NCT04759326

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hippotherapy
Description: Hippotherapy is an emerging specialized rehabilitation approach, performed on a specially trained horse via its movement at a walk by accredited health professionals (e.g., physicians, psychologists, physical therapists, occupational therapists, psychomotor therapists, chiropractors ...). The horse is an excellent support for temporary or consolidated disabilities, providing key elements of recovery for impairment, activity limitation, and participation restriction. It is a dynamic activity where the amplitude of movement of the patient's body transmitted by the horse is similar to the human walking (micro-movements of postural muscles). Moreover, through multimodal inputs (sensory, exteroceptive, proprioceptive, interoceptive), hippotherapy has a direct action on the individual's motor capacities and cognitive abilities. The degree of change relying on neuroplasticity is linked both to the relevance of the activity and to the intensity and frequency of the elements that constitute it.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Neurorehabilitation
Description: The neurorehabilitation therapy is an intervention from two or more disciplines (physiotherapy, occupational therapy, social work, psychology and other related disciplines, nursing) prescribed by a medical specialist (neurologist, neurosurgeon, oncologist, physiatrist). It is designed to be patient-centered, time-limited and functionally oriented, and aims to maximize activity and participation (social inclusion) using a biopsychosocial model.
Study: NCT06367738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin 1-30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: Psilocybin 1-30 mg
Study: NCT05961007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of IBI302(dose 1)
Description: IBI302(dose 1) intravitreal injection given as protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of IBI302(dose 2)
Description: IBI302(dose 2) intravitreal injection given as protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of IBI302(dose 3)
Description: IBI302(dose 3) intravitreal injection given as protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection of Aflibercept
Description: Aflibercept intravitreal injection given as protocol
Study: NCT05475756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrauterine Biological Barrier
Description: after Hysteroscopic adhesiolysis，use of Intrauterine Biological Barrier to repair uterine cavity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine Adhesion Barrier Gel
Description: after Hysteroscopic adhesiolysis，use of Intrauterine Adhesion Barrier Gel to repair uterine cavity
Study: NCT05063448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DadSpace
Description: A group educational support and mentoring program for perinatal fathers.
Study: NCT05292157

Intervention type: PROCEDURE
Intervention: shoulder arthroplasty
Description: range of motion (in degrees) measured in annual postoperative follow-up
Study: NCT05178797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiology taping technique with exercise therapy
Description: Kinesiology tape is a latex-free fiber that stretches longitudinally \& elastic with an acrylic adhesive. It is used to stimulate dermal mechanoreceptors, encourages sensory and mechanical stimuli resulting in reduction of clogging lymphatic flow which limits the circumference of the affected limb in the region where it is applied due to its flexibility and acts over the lymphatic system. However, exercise therapy is systematic movement program to strengthen muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression decongestive therapy
Description: It consists of two phases: First is the intensive phase (volume reduction phase), in this phase short stretch bandage, manual lymphatic drainage, skincare and exercises will be given for a period of 4 weeks.~In the second phase (maintenance phase), compression garments and exercises will be given to the patient for maintaining the limb volume or to reduce the risk of lymphedma.
Study: NCT06120790

Intervention type: OTHER
Intervention: 3 Oz water screen
Description: Patient will consume 3 oz of water continuously without stopping and then will be monitored for one minute post completion. Patient will complete this twice in the same session.
Study: NCT06237478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: At the timepoint of 10 min after operation beginning (T1), the basic HR, MAP and the HRV frequency indexes were recorded. Then glycopyrrolate 0.006 mg/kg was injected intravenously in Group L.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: At the timepoint of 10 min after operation beginning (T1), the basic HR, MAP and the HRV frequency indexes were recorded. Then glycopyrrolate 0.006 mg/kg was injected intravenously in Group H.
Study: NCT05408546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS23
Description: Monoclonal antibody to a2-antiplasmin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS23
Description: Monoclonal antibody to a2-antiplasmin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS23
Description: Monoclonal antibody to a2-antiplasmin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05611333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician-Led Remote Exercise Program Intervention
Description: The physician-led remote exercise program intervention consists of three 45-minute walking classes on Zoom per week for 4 weeks.
Study: NCT05420259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Exercise and Dietary Intervention (CEDI)
Description: The exercise program will be planned by an exercise physiologist and implemented by physiotherapists prior to rehabilitation physician assessment. In the first session patients will be evaluated by physiotherapist in order to allow personalization of exercise according to patient's age and functional capacity. In regard to diet, written materials will be given to patients and caregivers, namely a dietary plan, standard menus, recipes, and standard portions information.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Standard Care
Study: NCT05828485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: A single dose of MY008211A tablet was administered after fasting and high-fat, high-calorie feeding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MY008211A tablets
Description: A single dose of MY008211A tablet was administered after fasting and high-fat, high-calorie feeding
Study: NCT04786535

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Expanded Hemodialysis
Description: * Single-use Theranova 400 Dialyzer~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 500 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-flux Conventional Hemodialysis
Description: * Single-use high-flux hemodialyzer~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 500 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodiafiltration
Description: * Single-use high-flux hemodialyzer~* Post-dilution mode~* Minimum convective volume of 23 L~* Blood flow (Qb) minimum of 300 mL/min~* Dialysis flow (Qd) 700 mL/min~* Minimum therapy time of 4 hours~* Ultrafiltration necessary to achieve dry weight
Study: NCT05480267

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical treatment for lumbar spondylolisthesis
Description: There are two surgical treatments for lumbar spondylolisthesis; one is UBE, and another is MIS-TLIF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical treatment for lumbar spondylolisthesis
Description: There are two surgical treatments for lumbar spondylolisthesis; one is UBE, and another is MIS-TLIF
Study: NCT06385782

Intervention type: OTHER
Intervention: Antarctic environment
Description: . According to the different work content of the scientific expedition team members, and taking the average outdoor working time of 2 hours/day as the node, the scientific expedition team members are divided into outdoor groups (n=12) and indoor groups (n=10). Participants will be assessed on the day they enter the Antarctic station and leave.

Intervention type: OTHER
Intervention: Antarctic environment
Description: . According to the different work content of the scientific expedition team members, and taking the average outdoor working time of 2 hours/day as the node, the scientific expedition team members are divided into outdoor groups (n=12) and indoor groups (n=10). Participants will be assessed on the day they enter the Antarctic station and leave.
Study: NCT05363306

Intervention type: PROCEDURE
Intervention: implant insertion
Description: 4% articaine solution, a mid-crestal incision along the center of the edentulous bone ridge was performed. A full-thickness flap was elevated. The sites were prepared to permit insertion of transmucosal, external hex, implants (I-smart, I-RES, Lugano, Switzerland) at three different crestal levels, based upon vertical mucosa thickness measured at implant placement.~Owing to width crest, all implants were 3.75 mm in diameter and operators selected appropriate implant lengths (8, 10 mm) according to available bone crest height. All implants were not submerged and flaps were sutured around the transmucosal component.

Intervention type: PROCEDURE
Intervention: implant insertion
Description: 4% articaine solution, a mid-crestal incision along the center of the edentulous bone ridge was performed. A full-thickness flap was elevated. The sites were prepared to permit insertion of transmucosal, external hex, implants (I-smart, I-RES, Lugano, Switzerland) at three different crestal levels, based upon vertical mucosa thickness measured at implant placement.~Owing to width crest, all implants were 3.75 mm in diameter and operators selected appropriate implant lengths (8, 10 mm) according to available bone crest height. All implants were not submerged and flaps were sutured around the transmucosal component.

Intervention type: PROCEDURE
Intervention: implant insertion
Description: 4% articaine solution, a mid-crestal incision along the center of the edentulous bone ridge was performed. A full-thickness flap was elevated. The sites were prepared to permit insertion of transmucosal, external hex, implants (I-smart, I-RES, Lugano, Switzerland) at three different crestal levels, based upon vertical mucosa thickness measured at implant placement.~Owing to width crest, all implants were 3.75 mm in diameter and operators selected appropriate implant lengths (8, 10 mm) according to available bone crest height. All implants were not submerged and flaps were sutured around the transmucosal component.
Study: NCT05593562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH3127
Description: Oral 100 mg \[14 c\] SPH3127 mixed suspension
Study: NCT04338776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroLift
Description: The UroLift System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH).~During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rezum
Description: The Rezūm™ System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH.~The Rezūm System is manufactured by Boston Scientific and consists of a radiofrequency (RF) generator and a single-use transurethral delivery device.~The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released,reducing the volume tissue adjacent to the urethra.
Study: NCT05453591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colli-Pee UAS devices
Description: Colli-Pee UAS device variants will be evaluated during this study
Study: NCT05036421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 milligram
Description: antihyperglycemic medication
Study: NCT05373914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cudetaxestat (BLD-0409)
Description: Cudetaxestat - 250mg tablets (orally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cudetaxestat (BLD-0409)
Description: Cudetaxestat - 250mg tablets (orally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cudetaxestat (BLD-0409)
Description: Cudetaxestat - 250mg tablets (orally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control: Matching Placebo
Description: Placebo - 250mg tablets (orally)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control: Matching Placebo
Description: Placebo - 250mg tablets (orally)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control: Matching Placebo
Description: Placebo - 250mg tablets (orally)
Study: NCT06335563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AR glasses-assisted pulmonary nodule puncture localization
Description: Combined with placing positioning marks on the patient's body surface and tracing the needle entry point with the assistance of a CT scan gantry laser. Disinfect the area around the puncture needle point, and use 2% lidocaine for local infiltration anesthesia. The doctor wears augmented reality (AR) glasses, completes the connection between the AR glasses and the puncture target, and clicks on the puncture point plane through the puncture target needle tip. Calibrate the puncture position at any two points. After confirming that the patient has held his breath, quickly puncture the needle into the pleura and advance it to the planned puncture position according to the screen prompts. After the second CT scan is performed to confirm that the puncture needle is positioned at a reasonable position, the positioning hook wire is released and the puncture needle sheath is withdrawn.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CT-guided pulmonary nodule puncture localization
Description: Positioning markers are placed on the patient's surface and the first CT scan is performed. The needle insertion point and needle insertion depth are designed based on the two-dimensional CT scan image and the positioning marks. The location of the needle entry point was traced with the laser assistance of the CT gantry. Disinfect and puncture around the needle point, and use 2% lidocaine for local infiltration anesthesia. According to the designed needle path angle, the needle is first inserted under the skin, and a second CT scan is performed to confirm that the extension line of the puncture needle is within the nodule range. Then the needle is inserted to the target depth, and the third CT scan is performed. After confirming that the puncture needle is positioned at a reasonable position, the positioning hook wire is released and the puncture needle sheath is withdrawn.
Study: NCT05219370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis oil
Description: administration of different cannabis oil types as compared with placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis oil
Description: administration of different cannabis oil types as compared with placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis oil
Description: administration of different cannabis oil types as compared with placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis oil
Description: administration of different cannabis oil types as compared with placebo
Study: NCT05410873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MitoQ Compound
Description: Mitoquinol mesylate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04549298

Intervention type: OTHER
Intervention: No interventions
Description: No interventions - observational study

Intervention type: OTHER
Intervention: No interventions
Description: No interventions - observational study
Study: NCT05335278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 milligrams [Ofev]
Description: All patients will be given nintedanib 150 milligrams orally twice daily
Study: NCT05471271

Intervention type: OTHER
Group type: OTHER
Intervention: [18F]AlF-RESCA-IL2 PET scan
Description: Patients will undergo \[18F\]AlF-RESCA-IL2 PET imaging twice; the first \[18F\]AlF-RESCA-IL2 PET scan will be performed at baseline, before starting therapy. The second \[18F\]AlF-RESCA-IL2 PET scan will be performed after 2 weeks of treatment
Study: NCT04444440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Fluoroquinolone antibiotic.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pill
Description: Placebo Pill
Study: NCT05647603

Intervention type: OTHER
Intervention: data collection
Description: Information about contraception
Study: NCT04754659

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stentgraft
Description: Stentgraft treatment for AAA. Comparison between supra vs infrarenal fixation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stentgraft
Description: Stentgraft treatment for AAA. Comparison between supra vs infrarenal fixation.
Study: NCT04860778

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BDNF Essentials
Description: Participants will take two capsules, twice daily with water for 84 days.
Study: NCT05217316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Virtual Toothbrushing
Description: A supervised virtual toothbrushing performed once a week for all students by dental hygienist that will be performed through a prescheduled virtual appointment for each child. All virtual appointments will be conducted using the collaboration of two national platforms. Mawid, a Ministry of health (MOH) Central Appointment System, to be used by the subjects. And ANAT system, a Saudi Commission for Health Specialists (SCHS) application for the hygienists to use for their virtual supervision.
Study: NCT05306756

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fetal Blood Sampling (FBS)
Description: Vaginal examination, insert amnioscope through cervix, visualise fetal scalp, clean fetal scalp, apply ethyl chloride spray, wipe scalp with petroleum gel, small scalp scratch with sharp instrument, collect sample in heparinised capillary tube, analyse sample.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: digital Fetal Scalp Stimulation (dFSS)
Description: Vaginal examination, insert one or two fingers through cervix onto fetal scalp, rub fetal scalp digitally for approximately 30-60 seconds, withdraw fingers and observe CTG for 5-10 minutes.
Study: NCT06213103

Intervention type: PROCEDURE
Intervention: Patient cohort
Description: Collection of 6 blood tubes at the inclusion visit.

Intervention type: PROCEDURE
Intervention: Control cohort
Description: Collection of 6 blood tubes at the inclusion visit.
Study: NCT04861168

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: driving pressure guided ventilation
Description: driving pressure guided ventilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional protective lung strategy
Description: Conventional protective lung strategy